One mild exacerbation is a prediction, not a footnote

Design

Multicentre, prospective, community-based cohort with three-year follow-up

Population

915 community-dwelling adults with COPD: 41 (4%) with only mild exacerbations, 45 (5%) with one moderate exacerbation, 52 (6%) with frequent exacerbations and 777 (85%) with none in the preceding year

Primary outcome

Subsequent exacerbations and annual lung function decline over three years

Effect

Only mild exacerbations: rate ratio 1.67 (95% CI 1.11-2.51) for total and 1.76 (1.13-2.73) for moderate-to-severe exacerbations. One moderate exacerbation: 1.89 (1.31-2.73) and 2.29 (1.55-3.38). No significant difference in annual lung function decline

COPD risk stratification is built around frequent exacerbations and hospitalisation. Patients whose only event in a year was mild — treated at home with their own medication — or a single moderate one requiring an outpatient visit and a course of antibiotics or steroids, sit in the low-risk group by convention. This community-based cohort of 915 people with COPD, followed for three years, tested whether that convention holds.

It does not. Of the cohort, 41 (4%) had only mild exacerbations in the preceding year and 45 (5%) had exactly one moderate exacerbation. Compared with the 85% who had none, those with only mild exacerbations had 1.67 times the rate of subsequent total exacerbations (95% CI 1.11-2.51) and 1.76 times the rate of moderate-to-severe ones (1.13-2.73). A single moderate exacerbation carried rate ratios of 1.89 (1.31-2.73) and 2.29 (1.55-3.38). On CT, the mild-exacerbation group had more severe emphysema and the single-moderate group more air trapping than those with no events.

Lung function decline did not differ between groups, which is worth stating because it is the measure clinicians most often use to decide someone is stable. The actionable change is in the history: asking specifically about symptom episodes managed at home, which patients do not report as exacerbations because they never sought care for them, and treating a positive answer as a reason to review inhaled therapy and start a written action plan rather than to reassure.

• Ask specifically about episodes managed at home with existing medication — patients do not call these exacerbations
• Treat a single moderate exacerbation as a risk marker, not as an isolated event
• Do not use stable spirometry to conclude the patient is at low risk of future events
• Review inhaled therapy and provide a written action plan after any reported exacerbation
• Where CT already exists, note that emphysema and air trapping tracked with these low-burden histories

Why it matters

It contradicts the default that a patient who never needed a hospital is at low risk — and the group it identifies is the one clinicians reassure.

Don't overread it

This is observational: a history of mild exacerbation identifies people who will exacerbate again, but says nothing about whether treating differently changes that.

The statistics, in plain English

These rate ratios compare how often exacerbations occurred over three years, not the chance of having one. The groups are small — 41 and 45 patients — so intervals are wide (1.11-2.51 for the mild group), and the lower bounds sit close to 1.0: the direction is clear, the magnitude much less so. The absence of a difference in lung function decline is a genuine null within a three-year window, and does not mean the trajectories are the same over a decade.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.